PMC:7195088 / 16439-16576 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PubTator

    {"project":"LitCovid-PubTator","denotations":[{"id":"658","span":{"begin":44,"end":52},"obj":"Species"},{"id":"747","span":{"begin":7,"end":16},"obj":"Chemical"},{"id":"911","span":{"begin":58,"end":66},"obj":"Disease"}],"attributes":[{"id":"A658","pred":"tao:has_database_id","subj":"658","obj":"Tax:9606"},{"id":"A747","pred":"tao:has_database_id","subj":"747","obj":"MESH:D012254"},{"id":"A911","pred":"tao:has_database_id","subj":"911","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"r plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to n"}

    LitCovid-PD-MONDO

    {"project":"LitCovid-PD-MONDO","denotations":[{"id":"T80","span":{"begin":58,"end":66},"obj":"Disease"}],"attributes":[{"id":"A80","pred":"mondo_id","subj":"T80","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"r plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to n"}

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T70","span":{"begin":73,"end":78},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"r plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to n"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T114","span":{"begin":7,"end":16},"obj":"Chemical"},{"id":"T115","span":{"begin":22,"end":32},"obj":"Chemical"},{"id":"T116","span":{"begin":33,"end":37},"obj":"Chemical"},{"id":"T117","span":{"begin":73,"end":78},"obj":"Chemical"}],"attributes":[{"id":"A114","pred":"chebi_id","subj":"T114","obj":"http://purl.obolibrary.org/obo/CHEBI_63580"},{"id":"A115","pred":"chebi_id","subj":"T115","obj":"http://purl.obolibrary.org/obo/CHEBI_52999"},{"id":"A116","pred":"chebi_id","subj":"T116","obj":"http://purl.obolibrary.org/obo/CHEBI_10545"},{"id":"A117","pred":"chebi_id","subj":"T117","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"r plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to n"}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T106","span":{"begin":68,"end":109},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"r plus ribavirin plus interferon beta 1b in patients with COVID-19. Open-label RCT (NCT04276688, recruiting). Primary endpoint: time to n"}